- Schering-Plough Tries to Deal Its Way to Top
- Mar 13 | The Wall Street Journal | After spending the past four years patiently nursing midsize drug maker Schering-Plough Corp. back to health, veteran pharmaceutical-industry executive Fred Hassan resumed doing what he loves most: making deals. more
- Schering-Plough to Buy Akzo's Drug-Making Division for $14.4B
- Mar 12 | Bloomberg.com | Schering-Plough Corp. agreed to buy Akzo Nobel NV's drug-making division Organon for $14.4 billion in cash to gain the world's third-largest maker of birth-control pills and a stable of experimental medicines. more
- Biotech Interests Give FDA an Earful Over Regulations
- Mar 12 | San Jose Business Journal | Companies in Silicon Valley and around the country that are pioneering personalized medicine are anxiously awaiting new regulations from the FDA that could change the way they do business. more
- When Clinical Trial Results Just Say 'No'
- Mar 12 | The San Francisco Chronicle | Biotech companies often are able to bounce back from seeming disaster, thanks to deep reserves and partnerships. more
- Researchers Say FDA Increases Public Risks By Delaying Safety Data Release
- Mar 09 | The Boston Globe | Heart problems that pushed the painkillers Bextra and Vioxx off the market could have come to light earlier had federal regulators given outside researchers speedier access to raw safety data, according to a commentary written by Boston researchers. more
- Refining Data Mining
- Mar 08 | The RPM Report The FDA and pharmas are taking control of a powerful new tool for drug safety analysis. But there are concerns. more
- Analysis: New Call for FDA Openness
- Mar 07 | UPI | Two researchers Tuesday urged a change in FDA policies to allow the scientific community access to pharmaceutical manufacturers' clinical trial data in order to help reveal safety issues with new drugs. more
Feeds